Navigation Links
Targeted Anticancer Drugs - In Vitro Assessment and Non-Invasive Imaging of Patient and Tumor Status Will Determine Clinical and Commercial Success
Date:6/11/2008

New Medicine's Oncology KnowledgeBASE (nm/OK) tracks the development and use of patient and tumor assessment methodologies that represent one of the

most unique opportunities in the oncology field

LAGUNA NIGUEL, Calif., June 11 /PRNewswire/ -- Drug development in oncology is at the threshold of a new era that may finally fulfill the promise of cancer becoming a chronic disease. It is becoming apparent that in order to successfully treat patients with cancer it is necessary to accurately profile their disease and closely and continuously monitor its development. Coupling the use of targeted anticancer agents with patient selection and monitoring using highly specific in vitro tests and/or noninvasive imaging approaches is creating a unique and powerful method for the effective treatment of cancer.

New Medicine's Oncology KnowledgeBASE (nm/OK) that has anticipated this trend is a unique resource of every aspect of patient assessment to customize cancer treatment. A unique functionality of nm/OK allows users to specifically retrieve information regarding diagnostic/prognostic approaches by developer and cancer indication; target assessment (overexpression, amplification, mutation, methylation status) by drug, marker, and clinical trial protocol; and biomarkers for clinical trial surrogate endpoints, among others.

There are over 1,000 molecular targets linked to some aspect of neoplasia currently in preclinical or clinical development or on the market. Among the approximately 500 novel molecularly targeted agents that have been evaluated in clinical trials (multitargeted agents may appear in several groups) are:

41 agents targeting the vascular endothelial growth factor (VEGF) pathway

18 agents targeting the ErBb family (EGFr, HEr2, etc.)

13 agents targeting the Aurora kinase family

11 histone deacetylase inhibitors (HDAC)

13 agents targeting PDGF/PDGFr

11 agents targeting various heat shock proteins (Hsp)

10 drugs targeting various cyclin-dependent kinases (Cdk)

10 agents targeting c-Met

10 agents targeting IGF/IGFr

10 agents targeting FLT-3

9 agents targeting c-Kit

Additional targets include 20S proteasome; polyamine; 5T4 oncofetal antigen; a disintegrin and metalloproteinase domain 17 (ADAM17), TACE; acidic fibroblast growth factor (aFGF); activin receptor IIA (ActrIIA); adenosine deaminase; adenosine monophosphate (AMP); alpha5beta1 integrin; alphanubeta3 integrin; alphanubeta5 integrin; alpha-fetoprotein (AFP) receptor (RECAF); Akt; anaplastic lymphoma kinase (ALK); androgen receptor (Ar); angiopoietin-1; angiopoietin-2; APEX; ATP synthase [alpha] subunit; axl; Bap31; Bcl-xL; Bcl-2; bcr-abl/abl (including mutated forms); B-FN (ED-B fibronectin); carboxyanhydrase IX (CA IX); carcinoembryonic antigen (CEA); cathepsin K (CTSK); C-C chemokine receptor 4 (CCr4); CD105 (endoglin); CD13; CD19; CD20; CD22; CD25; CD3; CD30; CD33; CD38; CD4; CD40; CD55; CD56; CD70; CD74; CD80; CD95 (fas); CD137 (TNFrSF9); centromere-associated protein E (CENP-E); cGMP- PDE; checkpoint 1 (Chk1); chemokine (C-X-C motif) receptor 4 (CXCr4); Chk2; chondroitin sulfate proteoglycan 4 (CSPG4); C-Jun N-terminal kinase (JNK); c- Myb; c-Myc; colony stimulating factor 1 receptor (CSF1r); CTNNB (beta catenin); cyclin E; cyclin-dependent kinase inhibitor 1A (CDKN1A); cytochrome P450 1B1 (CYP1B1); cytotoxic T lymphocyte-associated antigen 4 (CTLA4); dihydrofolate reductase (DHFR); DT-diaphorase (DTD); E2F; E2F1; endocytic lectin receptors (EELr); endothelin A (ETA) receptor (ETAr); ephrin B4 (EphB4); epithelial cell adhesion molecule (EpCam); estrogen receptor-alpha (Er-alpha); eukaryotic translation initiation factor 4E (EIF4E); exonuclease III; farnesyl transferase (FTase); fibroblast growth factor 2 (FGF-2); FGFr; focal adhesion kinase (FAK); folate receptor (FOLr); FOLr1; galectin 3 (GAL3) receptor; gastrin 17 (G17); GD2; GD3; glioma-associated oncogene homolog (Gli- 1); glucoprotein A33 (GPA33); glutathione (GHS); glutathione S-transferase pi (GSTP1); glycinamide ribonucleotide formyltransferase (GARFT); glycoprotein NMB; B-lymphocyte stimulator (BLyS); gonadotropin-releasing hormone (GnRH); GnRHr; growth differentiation factor (GDF); hedgehog (Hh); heparanase; hepatocyte growth factor/scatter factor (HGF/SF); highly upregulated in liver cancer (HULC); human chorionic gonadotropin (hCG); hyaluronan (HA); hypoxia inducible factor 1 alpha (HIF-1alpha); interleukin 13 (IL-13); IL-13 receptor alpha2 (IL-13ralpha2); inosine monophosphate dehydrogenase (IMPDH); integrin alpha2; interleukin 6 (IL-6); interleukin 8 (IL-8); placental growth factor (PGF); Janus kinase 2 (JAK2); JAK3; kinesin-like spindle protein (KSP); Lewis y antigen; lymphocyte-specific protein tyrosine kinase (Lck); lymphotoxin (LT) beta receptor (LTBr); mammalian target of rapamycin (mTOR); MAP2K1; MAPK/ERK/kinase (MEK); MAPK/extracellular signal-regulated kinase (ERK) kinases (MEK); matrix metalloproteinase-2 (MMP-2); MMP-9; melanin; mesothelin (CAK1); methionine aminopeptidase 2 (MetAP2); motility-related protein-1 (MRP- 1); mucin 1 (MUC1); murine double minute 2 (MDM2), HDM2; N-acetylated alpha- linked acidic dipeptidase (NAALADase); N-cadherin (NCAD); neural precursor cell expressed, developmentally downregulated 8 (NEDD8); NFkappaB; nicotinic acid phosphoribosyltransferase (NAPRT); nucleolin; 17 alpha-hydroxylase/C17,20 lyase; ornithine decarboxylase 1 (ODC1); p38 mitogen-activated protein kinase (p38 MAPK); p53; P-glycoprotein (P-gp); phosphatidylinositol 3`kinase (PI3K); phosphatidyserine (PS); PI3K, catalytic, delta polypeptide (PI3KCD); PIK3C2A; plasminogen activator, urokinase (PLAU); polo-like kinase 1 (Plk1); poly (ADP- ribose) polymerase (PARP); programmed cell death-1 (PDCD1); prostate specific antigen (PSA); prostate stem cell antigen (PSCA); prostate-specific membrane antigen (PSMA); proteasome; protein kinase A type I (PKAI); protein kinase C (PKC); PKC-B; purine nucleoside phosphorylase (PNP); ras; R1 mRNA; R2 mRNA; Raf/B-Raf; Rad51; RET; ribonucleotide reductase (RNR); ribonucleotide reductase M2 polypeptide (RRM2); Ron; SH2-containing protein-tyrosine phosphatase 1 (SHP-1); signal transducer and activator of transcription 3 (STAT3); SLAM family member 7 (SLAMF7); somatostatin receptors (SSTr); somatotropin release inhibiting factor (SRIF) receptor (SRIFr); sphingosine kinase (SPHK); spingomyelin synthase; Src pathway; stromal derived factor 1 (SDF-1); superoxide dismutase 1, soluble (SOD1); survivin; telomerase reverse transcriptase (TERT, hTERT); telomerase; tenascin-C (TN-C); TGF-beta; TGF- beta2; thioredoxin-1 (trx-1); tie-2; toll-like receptor 7 (TLr7); TLr9; transferrin; transforming growth factor beta receptor I (TGFBr1); TGFbeta; tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor 1 (TRAIL-r1); TRAIL-r2; tumor suppressor candidate 2 (TUSC2), FUS1; tumor- associated glycoprotein 72 (TAG-72); vitamin D receptor (VDr); Von Willebrand factor; X-linked inhibitor of apoptosis protein (XIAP); etc. Hundreds of other molecular targets are in preclinical development.

New Medicine's Oncology KnowledgeBASE (nm|OK), residing at http://www.nmok.net, provides a complete knowledge environment in drug development in cancer. Contact us for an online demonstration of nm|OK.

Contact: Katie Siafaca

New Medicine, Inc.

Tel: (949) 830-0448; Fax: (949) 830-0887

E-mail: info@newmedinc.com

http://www.newmedinc.com

http://nmok.net

http://nmok.net/oksite/samprecords.html


'/>"/>
SOURCE New Medicine, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Study suggests brain tumors need treatment with multiple targeted drugs
2. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
3. Research suggests targeted treatment strategies for lupus
4. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
5. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Assessment of Its Phase I/II Trial of tgAAC94 for Inflammatory Arthritis
6. Gleevec, the targeted cancer pill, delivers more good news to patients
7. OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia
8. Light powered platinum more targeted and 80 times more powerful than similar cancer treatments
9. A major step toward a more targeted treatment for auto-immune diseases?
10. NeoStrata Clinical Findings Reveal Benefits of Combining Glycolic Acid Peels and Targeted Home Care With Microdermabrasion for Optimized Treatment of Photodamaged Skin
11. New study of targeted therapies for breast cancer -- model for global clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... Donor Network West, the organ procurement ... announced a partnership with San Ramon Regional Medical Center. Under the collaboration, the first ... a way to accommodate a more certain time frame for donor families for the ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... “Revolutionizing Cancer Care.” , The print component of “Revolutionizing Cancer Care” ... Pittsburgh/Cleveland, New York, Washington DC/Baltimore, and Seattle, with a circulation of approximately 250,000 ...
(Date:2/12/2016)... ... 12, 2016 , ... US Sport Camps is pleased to announce the addition ... Norwalk, serves as the host site and directing the camps is PGA Professional and ... successful camps in recent years around Des Moines and are fortunate to have such ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... explosive growth in the field of long term care. With that, says Patrick ... well-trained healthcare professionals in administrative roles in long term care environments. His company, ...
(Date:2/12/2016)... ... 2016 , ... With the exception of restorative dentistry, to date there has been no other ... approval by the FDA, there is a now a new protocol in stopping cavity progression; ... simple and quick to apply. The application is as simple as drying the tooth ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... AAIPharma Services Corp./Cambridge Major Laboratories, Inc. ... development services for the pharmaceutical and biotechnology industries, ... in its Charleston, SC ... recent investments. Charleston ... with small-scale lyophilization. The site has invested in ...
(Date:2/11/2016)... ANKENY, Iowa , 11 de fevereiro de ... a inauguração de sua fábrica de soroalbumina bovina ... Nova Zelândia. A fábrica fica na Ilha Norte ... Loop "), desenvolvido e estabelecido na fábrica da ... Iowa . O projeto e instalação dos ...
(Date:2/11/2016)... Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 ... (APAC) breast cancer market will experience considerable expansion from $1.9 ... Compound Annual Growth Rate (CAGR) of 8.5%. --> ... states that the Asia-Pacific (APAC) breast ... 2014 to $3.4 billion by 2021, at a Compound Annual ...
Breaking Medicine Technology: